In 2007, Professor Hans J. Schlitt from the University Hospital Regensburg in Germany performed the first associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) on a patient with hilar cholangiocarcinoma. During exploratory laparotomy, the surgeon divided the liver along the falciform ligament and ligated the right branch of the portal vein to promote the enlargement of the future liver remnant (FLR). CT on the 8th postoperative day showed that the FLR volume increased by 94%, and the second-stage hepatectomy was completed the next day [1, 2]. In 2012, Professor Schnitzbauer et al. reported and reviewed 25 cases of two-staged liver resection performed in five medical centers in Germany from September 2007 to January 2011. On average, CT scans on the 9th postoperative day after the first stage revealed an increase of FLR by a mean value of 74% (21%–192%) without irreversible post-hepatectomy liver failure (PHLF). The in-hospital mortality rate was 12%, and the median 6-month survival rate was 86% [1]. Then, the ALPPS procedure immediately gained the attention of the hepatobiliary surgery community. In the same year, Professor Santibanes E. and Professor Clavien P. A. published a paper in the Annals of Surgery, using the “associating liver partition and portal vein ligation for staged hepatectomy” with “ALPPS” as the acronym to name this novel procedure [3], that is, classical ALPPS that we know today.